{"organizations": [], "uuid": "b01eaef3adf65645275ccbaed823a23d47254337", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-incyte-corp-co-syros-pharmaceutica/brief-incyte-corp-co-syros-pharmaceuticals-have-entered-into-target-discovery-research-collaboration-and-option-agreement-idUSFWN1P30Q1", "country": "US", "domain_rank": 408, "title": "BRIEF-Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.494, "site_type": "news", "published": "2018-01-08T21:20:00.000+02:00", "replies_count": 0, "uuid": "b01eaef3adf65645275ccbaed823a23d47254337"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-incyte-corp-co-syros-pharmaceutica/brief-incyte-corp-co-syros-pharmaceuticals-have-entered-into-target-discovery-research-collaboration-and-option-agreement-idUSFWN1P30Q1", "ord_in_thread": 0, "title": "BRIEF-Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "incyte corp", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "brief-incyte corp - co", "sentiment": "negative"}, {"name": "incyte", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Incyte Corp:\n* INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT\n* INCYTE-‍UNDER AGREEMENT, SYROS TO USE ITS GENE CONTROL PLATFORM TO IDENTIFY NOVEL THERAPEUTIC TARGETS WITH FOCUS IN MYELOPROLIFERATIVE NEOPLASMS​\n* INCYTE - CO TO HAVE EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE ANY THERAPIES UNDER COLLABORATION THAT MODULATE VALIDATED TARGETS​\n* INCYTE - UNDER DEAL, CO TO GET OPTIONS TO GET EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM COLLABORATION FOR UP TO SEVEN VALIDATED TARGETS\n* INCYTE CORP - ‍ UNDER TERMS , CO TO PAY SYROS $10 MILLION UPFRONT AND PURCHASE A TOTAL OF $10 MILLION IN SYROS COMMON STOCK AT $12.61 PER SHARE​\n* INCYTE - SHOULD INCYTE EXERCISE ALL OF ITS OPTIONS UNDER DEAL, SYROS COULD GET UP TO $54 MILLION FROM INCYTE IN TARGET SELECTION & OPTION EXERCISE FEES\n* INCYTE CORP - SYROS COULD ALSO RECEIVE UP TO $50 MILLION IN DEVELOPMENT AND REGULATORY MILESTONES, AS WELL AS UP TO $65 MILLION IN COMMERCIAL MILESTONES\n* INCYTE CORP - SYROS WOULD ALSO BE ELIGIBLE TO RECEIVE LOW SINGLE-DIGIT ROYALTIES ON SALES OF PRODUCTS RESULTING FROM COLLABORATION Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T21:20:00.000+02:00", "crawled": "2018-01-09T17:17:53.020+02:00", "highlightTitle": ""}